Urothelial Cancer Treatment Market Share, Trends, Size, Research and Forecast 2019-2025

The global urothelial cancer treatment market is estimated to witness significant growth during the forecast period. The rising frequency of urothelial cancer among middle-aged and older-aged people is driving the market. About 90% of the urothelial cancer patients are older than 55 years and the average age of people are diagnosed with urothelial cancer is 73 years. Due to the growing incidence of urothelial cancer, drug manufacturers are making efforts to develop innovative cancer therapies. Immunotherapy has less toxicity than chemotherapy which makes it more suitable for the elderly population. Immunotherapy shows a rapid and sustained response as compared to chemotherapy. The companies present in the market are focused on developing innovative diagnostic and treatment solutions for urothelial cancer.

A full report of Global Urothelial Cancer Treatment Market is available at: https://www.omrglobal.com/industry-reports/urothelial-cancer-treatment-market

Immunotherapy, also called biologic therapy. This therapy is intended to boost the natural immune system to fight cancer. Immunotherapy is of two types, local therapy, and systemic therapy. Bacillus Calmette-Guerin (BCG), a standard Immunotherapy drug, used for the treatment of urothelial cancer. Through the catheter, it is directly placed into the bladder. Interferon (Roferon-A, Intron A, Alferon), another type of Immunotherapy it is combined with BCG for the treatment of urothelial cancer. Some of the major drugs used in Immunotherapy are Atezolizumab (Tecentriq), Avelumab (Bavencio), Durvalumab (Imfinzi), Nivolumab (Opdivo), Pembrolizumab (Keytruda), and others.

To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/urothelial-cancer-treatment-market

The companies present in the market are focused on developing innovative treatment solutions for urothelial cancer treatment. For instance, in May 2016, the company got FDA approval for its cancer immunotherapy Tecentriq (atezolizumab) for the treatment of a specific type of advanced bladder cancer. Further, in 2017, the FDA granted approval to nivolumab (Opdivo) for the treatment of bladder cancer. This makes nivolumab one of the immune checkpoint inhibitor among 5 inhibitors approved for the treatment of bladder cancer. Such advancement is expected to boost the growth of the global urothelial cancer treatment market in the near future.

Global Urothelial Cancer Treatment Market Segmentation

By Therapy Type

• Chemotherapy
• Immunotherapy
• Others ( Targeted Therapy & Radiation Therapy)

For more customized data, request for report customization @ https://www.omrglobal.com/report-customization/urothelial-cancer-treatment-market

Global Urothelial Cancer Treatment Market– Segment by Region

North America

• United States
• Canada

Europe

• Germany
• United Kingdom
• France
• Spain
• Italy
• Rest of Europe

Asia-Pacific

• China
• Japan
• India
• Rest of Asia-Pacific

Rest of the World

• Middle East & Africa
• Latin America

Company Profiles

• Adaptimmune Therapeutics Plc
• Alligator Bioscience AB
• Amgen, Inc.
• AndroScience Corp.
• AstraZeneca PLC
• Bristol-Myers Squibb Co.
• Eisai Co. Ltd.
• Eli Lilly and Co.
• F. Hoffmann-La Roche AG
• GlaxoSmithKline PLC
• Johnson & Johnson Service, Inc.
• Merck & Co, Inc.
• Novartis AG
• Pfizer, Inc.
• Sanofi S.A.
• Sun Pharmaceutical Industries, Ltd.
• Teva Pharmaceutical Industries, Ltd.
• Vault Pharma, Inc.

Media Contact:

Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +1 646-755-7667, +91 7803040404

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

For More Information, Visit https://www.omrglobal

This release was published on openPR.